Abdallah Abbas’ Post

Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600–Mutant Pediatric High-Grade Glioma 51% children weee alive at median follow up of 25 months Top adverse effects were fever and headache

TO CELEBRATE CANCER SURVIVORS DAY My platform is medication adherence. It is a critical variable in improving health outcomes for cancer survivors, especially for those managing chronic conditions like diabetes. Ensuring that cancer survivors consistently take their prescribed medications as directed can significantly reduce the risk of complications and enhance their overall quality of life. I only provide solutions, not excuses. Personalized patient education can instill the importance of their medications and how to take them correctly. Incorporating a structured protocol- a standard set of questions that benchmark a patients level of adherence and follows that patient over time through a tailored intervention offers proven results. Involving family members or caregivers in the medication management process can provide extra support and accountability. The MMAS digital intervention program can be customized and has been validated for a number of medical conditions in numerous languages including: OS-MMAS (Osteoporosis Specific) P-MMAS (Pediatric) WD-MMAS (Wilsons Disease) BC-MMAS (Breast Cancer) COPD CKD Many specific medications as well

A recent study published in JAAOS: Global Research and Reviews reveals a concerning trend of increasing Scurvy incidence in pediatric patients in the US. The disease, caused by vitamin C deficiency, more than tripled from 2016 to 2020, affecting younger males from low-income households. Patients often have concomitant diagnoses like autism spectrum disorder and obesity. The study emphasizes the importance of considering Scurvy in differential diagnoses to prevent delayed treatment and associated burdens.

Another exciting development in pediatric healthcare! Seattle Children's prepares to pioneer the first groundbreaking clinical trial known as REACT-01, featuring CAR T-cell therapy designed specifically for children suffering from lupus REACT-01, which stands for Remission through Engineered CAR T-cells in Autoimmunity and Chronic Inflammation Trial, sheds light on an entirely novel approach for young patients. Those participating will receive genetically modified T-cells, engineered to combat the rogue immune cells responsible for the symptoms of lupus, to reduce or even eliminate the need for traditional lifelong medication. The study will enroll 12 patients under 18, navigating through age-grouped phases starting with those at least 17 years old. The first phase will enroll three individuals aged at least 17 years, before moving to the second phase and enrolling three individuals aged 12-17 years. Then, phase 3 will also include children aged 5-12 years. Follow the journey of Dr. Shaun Jackson and his team eyeing a future where children of all ages are unshackled from the relentless grip of lupus. #Autoimmune #LupusResearch #SLE #CART #CellTherapy #ChildrensHealth #Pediatric #FDA #ElixirAssociates

Take home messages of lecture ' bacterial meningitis' 1.Avoidance of delay in administering AB. 2.Generally some AB should not be considered for treatment due to poor penetration as colistin ,tazocin (piperacillin/tazobactam ) ,azithromycin , clarithromycin , cefazolin and clindamycin ). 4.IV Route of administration of AB because of the general limitation in antimicrobial penetration into the CSF even if patient clinically improved. 5.Higher doses of AB to ensure adequate CNS penetration across blood brain barrier. 6.Use of bactericidal drugs. 7.Clinical data supporting use of corticosteroids A. Pediatric patients (>6 weeks) with H. influenzae meningits less hearing loss and other neurologic sequelae in infants and children. B. Adults with S. pneumoniae meningitis,associated with decreased mortality. 9.Selection of AB must be empiric based on patient age and other conditions (e g secondary to trauma, neurosurgery, presence of CSF shunt). 10.Duration of therapy based on isolated pathogen, immune status, timeliness of clinical response. 11. Don't forget patient counseling about vaccination .

🚨 Research Alert! 🚨 I'm excited to share my new and intriguing study! 🌟 We examined the rising prevalence of Crohn's disease (CD) in children and adolescents, focusing on how factors such as age, gender, initial disease location, and treatment impact the time to achieve improvement in disease activity. Key findings include: 🔸 Younger age at onset is associated with more severe disease activity. 🔸 Treatment with Anti-TNF (Infliximab) is linked to a better prognosis, especially when combined with enteral nutrition or immunosuppressants. This study, drawing from data in the Saxon Pediatric IBD Registry, underscores the importance of personalized treatment approaches. Read the full study here: https://lnkd.in/epX2WYTm #PediatricIBD #CrohnsDisease #MyResearch #MedicalResearch #Infliximab #PersonalizedMedicine

A recent study from Indiana University School of Medicine reveals a significant correlation between primary ciliary dyskinesia (PCD) and asthma in children. The research, published in JAMA Network Open, indicates that children with PCD are 22 times more likely to have asthma compared to those without the disorder. This finding underscores the necessity for routine asthma screening in children with PCD and suggests that some asthma cases may involve undiagnosed PCD. The study analyzed 266 pediatric records, highlighting the importance of recognizing overlapping symptoms for improved respiratory outcomes in young patients.

🔬 Student Research Spotlight: Lindsey Maclay Mentor: Dr. S. Ali Husain   Lindsey Maclay, alongside her mentor Dr. Syed Ali Husain, uncovers disparities in access to timely waitlisting among pediatric kidney transplant candidates. Their research revealed significant differences in preemptive waitlisting among pediatric patients, particularly among female, Hispanic, Black, and publicly insured patients. They also identified differences in access to pediatric prioritization among these same populations. Lindsey's work highlights the need for policy revision to address disparate access to pediatric priority in kidney allocation and ensure all children have equitable access to life-saving kidney transplants. Read more here: https://lnkd.in/e98TP7BN

C(min) should not be used as a surrogate marker for a therapeutic AUC(0–24) in pediatric patients https://buff.ly/4asr2Z7

Join us on October 8th as we celebrate and uplift the patients of Allen-Herndon-Dudley syndrome (AHDS) on World MCT8-AHDS Day. Allen-Herndon-Dudley syndrome, also known as MCT8 deficiency, is a rare genetic disease which appears most frequently in males and affects the thyroid hormone transporter called MTC8. Patients experience both hypothyroidism (not enough thyroid hormone) in the brain while simultaneously suffering from hyperthyroidism (too much thyroid hormone) in the rest of their body. This causes moderate to severe developmental delay, increased heartrate, low muscle strength, inability to gain weight/malnutrition, heart arrhythmia, and cardio-respiratory failure. Those with Allen-Herndon-Dudley syndrome sustain damage to the brain as early as the first trimester of pregnancy. Because this cannot be reversed or repaired once it has occurred, it is vitally important that a patient is diagnosed and receives a treatment plan as close to birth as possible. However, even with early diagnosis, these children will require extensive support from caregivers. Most will not develop the ability to walk or talk independently, and they will rely on others when it comes to their hygiene, feeding, administration of medicine, and other daily activities. Although this is undeniably a challenging condition, there is hope for those who are managing this rare disease – new therapies in development for MCT8-AHDS patients and their caregivers. At Anovo, we are proud to administer the Egetis Therapeutics AB Early Access Program (EAP) for MCT8-ADHS patients. Together, we’re making strides toward potential future treatments for patients with this rare disease.